Modular ligands for dirhodium complexes facilitate catalyst customization by Bachmann, Daniel et al.
 1 
 COMMUNICATION 
DOI: 10.1002/adsc.201((will be filled in by the editorial staff)) 
Modular ligands for dirhodium complexes facilitate catalyst 
customization 
Daniel G. Bachmann,a  Pascal J. Schmidt,a Stefanie N. Geigle,a Antoinette Chougnet,a 
Wolf-Dietrich Woggon,a and Dennis G. Gillinghama* 
a Department of Chemistry, University of Basel, St. Johanns-Ring 19, 4056 Basel, Switzerland. Fax:  (+41)-61-267-
0976; Phone:  (+41)-61-267-1148; e-mail: dennis.gillingham@unibas.ch  
Received: ((will be filled in by the editorial staff)) 
Supporting information for this article is available on the WWW under http://dx.doi.org/10.1002/adsc.201######.((Please 
delete if not appropriate)) 
Abstract. Although stereoselectivity is often the focus of 
ligand optimizations in catalysis, ligand modularity can be 
used to control many other properties of catalysts. For 
example solubility, amenability to purification, and steric 
shielding of sensitive catalytic intermediates are all 
important, but seldom appreciated, functions of ligands. We 
describe a brief and modular approach to various homo- and 
heteroleptic lantern-type rhodium(II) complexes and 
perform benchmarking studies with the new catalysts in 
common rhodium(II)-catalysed reactions. We demonstrate 
the power of ligand modularity by creating catalysts 
customized for aqueous catalysis or for applications in 
chemical biology. 
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We became interested in tethered bis-dicarboxylate 
rhodium(II) complexes in the context of our recent 
studies on metal-carbenoid based nucleic acid 
alkylation.[1] To further develop this technology we 
needed a set of rhodium(II) complexes with stable and 
modular ligands that still performed well in typical 
rhodium(II)-catalyzed reactions, particularly in water. 
Most rhodium complexes are highly insoluble in water 
and not readily amenable to modification.[2] We settled 
on the tethered bis-carboxylate structure because we 
thought its increased stability,[3] as well as its potential 
to intercalate DNA,[4] could deliver performance 
improvements in comparison with Rh2(OAc)4. The 
ligand introduced by Du Bois and co-workers[5] was 
chosen as a starting scaffold but two major problems 
prompted us to change tack: first, creating a library of 
ligands proved synthetically cumbersome and second, 
controlling mono- versus double-substitution in the 
rhodium carboxylates was unpredictable. Inspired by 
previous work from Bonar-Law in creating dirhodium-
based metal-organic architectures,[6] we examined 
dicarboxylate ligands derived from 1,3-benzenediols 
(see Scheme 1). This construct maintains the essential 
structural features of the espino ligand, but has the 
advantage of modularity since numerous 1,3-
benzenediol derivatives are commercially available. 
Moreover, since Bonar-Law used these dicarboxylates 
to create well-defined supramolecular objects the 
coordination of each ligand needed to be precisely 
controlled, providing valuable information for our 
own studies. 
 
Scheme 1. Modular approach towards mono- and bis-
substituted rhodium(II) complexes. See the ESI pages S2-
S6 and S14-S19 for detailed protocols. 
The syntheses of the various homo- and heteroleptic 
rhodium(II) complexes we have prepared are shown in 
Scheme 1. Using the conditions developed by Bonar-
Law the monobiscarboxylate complex 1 is obtained in 
60% yield after three hours in N,N-dimethylaniline. 
However, for ligands with electron withdrawing 
groups at C5 (10b-d) milder conditions were 
necessary: Rh2(OAc)2(TFA)2 in DCE at 60-70°C with 
small amounts of EtOAc as co-solvent led to 
acceptable yields (31% for 2, 27% for 3, and 35% for 
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4). The yields are low to moderate, but this is a typical 
feature of syntheses of rhodium(II) complexes; in 
many cases substantial amounts of starting material 
can be recovered and recycled. Unfortunately, 
attempts to perform a second substitution to access the 
heteroleptic complexes using Bonar-Law’s conditions 
led to low yields and mixtures of products. We 
therefore turned to Taber’s original procedure 
involving a portion-wise addition of the ligand.[7] 
Through the combination of these protocols we have 
been able to synthesize new rhodium(II) complexes 
containing a variety of functional groups (Scheme 1).  
Shown in Scheme 2 is the full collection of 
dicarboxylate ligands 10a-e we have synthesized thus 
far starting from commercial C5-substituted 1,3-
benzenediols 8a-e. Diesters 9a-e were synthesized by 
double O-alkylation with ethyl-2-bromoisobutyrate 
and a mixture of K2CO3 and Cs2CO3 in yields between 
77 and 99%. Final hydrolysis was accomplished with 
LiOH to afford the desired dicarboxylate ligands 10a-
e in excellent yield, bearing a variety of functional 
groups poised for further modification such as amide 
bond formation (2 or 6), Pd-catalyzed cross coupling 
(3) or condensation reactions (4, 6, 7).  
Scheme 1. Compounds 8a-e are commercially 
available. i) Ethyl-2-bromoisobutyrate, K2CO3, 
Cs2CO3, DMF, 80°C, 12 h, 47-82% ii) LiOH●H2O, 
MeOH/H2O 2:1, 60°C, 3 h, 79-99% or THF/H2O 1:1, 
60°C, 20 h, 77-84% for 10b and 10e, respectively. 
 
To probe the impact of the ligand on catalysis 
dirhodium(II) catalysts 5, 6, and 7 were tested in a 
typical intramolecular nitrene insertion reaction of 
sulfamate ester 11 (Table 1). Catalyst 5 leads to 
reaction at a similar rate as the Du Bois catalyst (see 
entries 1 & 2); only at 0.1 mol% loading does the Du 
Bois system prove superior,[5] still delivering complete 
conversion while 5 stalls at 35% (data not shown). For 
operational simplicity and to allow comparisons at 
early time points reactions with catalysts 5-7 were also 
run at 25 ˚C. At 25 ˚C 5 reached complete conversion 
in 2 hours (entry 3), while 6 required 4 hours (entry 4). 
Catalyst 7 performed best of all, giving complete 
conversions at 60 minutes (entry 5). Catalyst 7 was 
further tested with some potential interfering additives 
to determine its robustness.[8] We chose protic or 
Lewis basic additives since our primary goals are for 
aqueous catalysis. Although methanol and acetic acid 
both attenuate the reactivity of 7, complete 
conversions were still achieved in reasonable reaction 
times (entries 6 & 7). The powerful Lewis base 
trimethylamine, however, inhibited the reaction (entry 
8). The superiority of catalyst 7 in nitrene insertion 
may be a result of the more electron deficient character 
of the ligand, which would make the catalyst difficult 
to oxidize. Du Bois has shown that oxidative damage 
to catalysts is the primary mode of catalyst 
deactivation in nitrene insertion.[9] 
 
Table 1. Benchmarking of catalysts in a nitrene 
insertion 
entry cat. additive Temp 
(˚C) 
time 
(min)a) 
1 5 - 40 45b) 
2 Rh2(esp)2 - 40 45 
3 5 - 25 120c) 
4 6 - 25 240c) 
5 7 - 25 60c) 
6 7 MeOH 25 120c) 
7 7 AcOH 25 240c) 
8 7 NEt3 25 n.r.c) 
a) time to reach ≥95% conversion; for a complete 
tabulation of time-point measurements see the ESI 
pages S7-S8; b) 98% isolated yield after 
chromatography; c) determined by 1H NMR 
monitoring of the reactions in CD2Cl2. 
 
In a second set of benchmarking experiments the new 
set of catalysts were tested in C-H insertion reactions 
to make β- or γ-lactams (see 14a and 14b in Table 
2).[10] Comparison of entries 1-4 indicate that 5 
performed best for β-lactam formation by C-H 
insertion. This trend was also seen in the formation of 
a γ-lactam (cf. entries 8-11), although with this 
substrate 7 also worked well. The reaction times of 20 
and 10 minutes for the reactions in entries 2 and 9 
respectively are rapid for this reaction class. As a point 
of comparison the conditions in entry 8 are the 
previous best results for this transformation; here 
higher loading (3 mol%), higher temperature (70 ˚C in 
toluene), and a longer reaction time were needed (60 
minutes). 
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Table 2. Benchmarking of catalysts in C-H insertion 
reactions 
entry cat. additive product 14:15a) time 
(min)b) 
1 Rh2(OAc)4 - N
O
tBuPh
EtO2C
14a
 
19:1 270b) 
2 5 - 14a >49:1 20c) 
3 6 - 14a >49:1 120b) 
4 7 - 14a >49:1 60b) 
5 5 MeOH 14a >49:1 30b) 
6 5 AcOH 14a >49:1 150b) 
7 5 NEt3 14a - n.r. 
8 Rh2(OAc)4 - 
14b
N
O
Et
Ac
 
4:1 60b) 
9 5 - 14b 9:1 10d) 
10 6 - 14b 8:1 60b) 
11 7 - 14b 9:1 10b) 
a) ratio measured by 1H NMR analysis of crude 
reaction mixtures; b) time to reach ≥95% conversion 
according to 1H NMR monitoring of the reactions in 
CD2Cl2; for a complete tabulation of intermediate 
time-points see the ESI pages S8-9; c) 76% isolated 
yield after silica gel chromatography; d) 80% isolated 
yield after silica gel chromatography. 
 
The modularity of the catalyst system opens new 
vistas in controlling rhodium-carbene chemistry. For 
example, although aqueous rhodium(II) catalysis is 
well-established, moderate water solubility limits the 
scope of most catalysts. Catalysis in water has 
therefore been limited to soluble variants,[11] systems 
that contain cosolvents or detergents,[12] or for 
catalysts bearing peptide ligands.[13] The emerging 
importance of rhodium catalysis in chemical biology 
demands that more efficient water-soluble systems be 
developed.[14] The heteroleptic dirhodium(II) complex 
6 bearing a ketone functionalized ligand (10c) and a 
carboxylate functionalized ligand (10b) was found to 
be completely water soluble above the pKa of the 
carboxylate. This simple feature of complex 6 
demonstrates the power of modularity in controlling 
the bulk properties of a catalyst. As a proof-of-concept 
for the potential of 6 in aqueous catalysis we tested the 
β-lactam formation under aqueous conditions. In the 
intramolecular C-H insertion catalyst 6 required lower 
loading (0.5% vs 1-2%) and less time (10 min vs 0.5-
24h) than the previous best catalyst.[11] Dirhodium(II) 
catalysts with high TOF in water are rare and therefore 
catalyst 6 represents a good candidate for future 
development in aqueous catalysis (an additional 
example of 6’s potential in aqueous catalysis is 
provided in the ESI page S11). 
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Scheme 3 Aqueous intramolecular C-H insertion with 6 
 
We designed the ligand to combine structural 
flexibility without perturbing rhodium’s primary 
ligand sphere, thus facilitating sophisticated 
modifications of the rhodium complexes (Table 3). 
Aldehyde-bearing complex 4 was condensed with a 
variety of hydrazide derivatives of small molecules 
that are important in chemical biology to create 
dirhodium(II) complexes with tailored properties. In 
particular conjugates with biotin, folic acid, maleimide, 
and Hoechst dye were all prepared without event. The 
maleimide and biotin complexes could be used in 
metalloenzyme development;[15] while biotin could 
also be used for directing the catalyst to histones,[16] 
potentially offering a way to modify them. 
Table 3. Conjugation of complex 4 with a variety of useful 
small molecules 
a) Please see the ESI for detailed reaction conditions. b) 
Refers to isolated yield after preparative reverse-phase 
HPLC. 
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Many dirhodium(II) complexes have been shown to 
have DNA binding properties comparable with 
cisplatin;[4] and the folate receptor is known to be 
overexpressed on cancer cells due to increased nutrient 
requirements.[17] By combining these properties, 
folate-rhodium conjugates might therefore provide 
cancer-selective cytotoxins. The γ−acid of folate has 
previously been shown to be amenable to modification 
without interfering with receptor binding[18] and we 
were pleased to find that a hydrazide installed at this 
position led to smooth and selective condensation with 
complex 4 (51% yield, entry 2, Table 1). 
It has recently been shown that fluorescently 
labelled dirhodium(II) complexes are taken up by cells 
and accumulate in lysosomes and mitochondria.[19] No 
dirhodium(II) could be detected in the nucleus, an 
unfortunate reality given that dirhodium(II)’s 
antiproliferative activity is likely a consequence of its 
interaction with DNA.[20] We envisioned 
reprogramming the cellular fate of rhodium by 
attaching a traceable molecule known to target DNA 
and we selected the common nuclear staining dye 
Hoechst 33258 for proof-of-concept (entry 4, Table 1). 
Indeed we were very pleased to find that after 30 min 
of incubation with a 100 µM solution, fluorescence 
microscopy revealed the accumulation of 19 in cell 
nuclei of live U87 brain tumor cells (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Selective Rh(II) complex uptake into cell nuclei 
of live U87 cells: (a) cells under white light, (b) cell nuclei 
stained by complex 19b, (c) overlay. See the ESI page S24 
for a full description of the staining protocol and control 
experiments. 
The strapped bidentate ligands were an important 
development for dirhodium(II) chemistry;[3, 5, 7] here 
we add the innovation of a modular handle to this class 
of catalysts. The modularity facilitates rapid bespoke 
customization, as demonstrated by the reactions in 
Scheme 3 and the new catalysts in Table 1. We are 
currently exploring the potential biological 
applications of the catalysts described in Table 1. But 
the ability to redirect dirhodium catalysts to the cell 
nucleus through simple Hoechst conjugation is already 
indicative of the enabling power of modular ligands. 
Now that we can localize rhodium to DNA the next 
step is to understand whether this specificity impacts 
rhodium’s anti-cancer properties. 
Experimental Section 
Representative rhodium complex synthesis (3): Diacid 
10e (20 mg, 0.055 mmol) was added into a dry round 
bottom flask under a nitrogen atmosphere as a solution 
in EtOAc and all volatiles were subsequently removed 
under reduced pressure. Then 2 ml of 1,2-
dichloroethane were added and followed by 
Rh(OAc)2(TFA)2 (30 mg, 0.055 mmol). The green 
solution was immersed into a preheated oil bath at 
60°C and stirred for 7h. At this time most of the ligand 
was consumed and the amount of by-products was 
lowest compared to desired complex 3. After cooling 
to room temperature, all volatiles were removed under 
reduced pressure. The obtained green solid was 
subsequently dissolved in 1 mL of DMSO and injected 
into the preparative HPLC (0.1% TFA in H2O, 2% to 
70% CH3CN over 30 min. tR = 27 min) and the product 
eluted as a purple band. After lyophilisation, 10 mg 
(0.015 mmol, 27%) of 3 were obtained as a green solid. 
3 mg of Rh2(OAc)2(TFA)2 (tR = 26 min) were re-
isolated. 1H NMR (500 MHz, 5 % v/v MeOH in 
CDCl3): δ 6.67 (d, J = 2.1 Hz, 2H), 5.93 (t, J = 2.1 Hz, 
1H), 1.89 (s, 6H), 1.36 (s, 12H). 13C NMR (126 MHz, 
5 % v/v MeOH in CDCl3): δ 192.5, 191.7, 156.4, 121.8, 
118.1, 107.7, 81.1, 25.0, 23.6. HRMS (ESI) m/z: calcd. 
for C18H21BrO10Rh2Na+ [M+Na]+ 704.8320 found: 
704.8311. 
 
Representative C-H insertion (14a): To a solution of 
diazo 13a (20.8 mg, 68.3 µmol) in CH2Cl2 (405.4 µL) 
a stock solution of 5 (278.8 µL, 4.91 mM in CH2Cl2, 2 
mol %) was added and the reaction mixture was stirred 
at rt. Analysis of the mixture via 1H-NMR 
spectroscopy after 10 min showed full conversion of 
the starting material to the single cis β-lactam 14a. The 
solvent was removed under reduced pressure and the 
residue was purified by flash chromatography (10 g 
C18 reverse phase silica, MeCN/0.1% TFA in H2O). 
The corresponding fractions were combined, the 
solvent removed under reduced pressure to obtain β-
lactams 14a and 15a (14.3 mg, 51.7 µmol, 76 %) as 
white solid. These could be further separated by 
preparative reverse phase HPLC. Characterization for 
14a: 1H-NMR (400 MHz, CDCl3) δ 7.47 – 7.31 (m, 
5H), 4.90 (d, J = 6.3 Hz, 1H), 4.21 (d, J = 6.2 Hz, 1H), 
3.76 (q, J = 7.1 Hz, 2H), 1.31 (s, 9H), 0.84 (t, J = 7.1 
Hz, 3H, 14a). 13C-NMR (101 MHz, CD2Cl2) δ 166.6, 
163.3, 137.6, 129.1, 128.8, 127.8, 61.3, 59.6, 57.0, 
55.3 28.3. 
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For complete experimental details please see the 
electronic supplementary information. 
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